A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

This phase Ib/II study is testing FWD1802 — a new targeted therapy — in combination with other drugs for people with estrogen receptor-positive (ER+), HER2-negative breast cancer that has spread or cannot be surgically removed and has progressed after prior hormonal treatments. **You may be eligible if...** - You are postmenopausal or premenopausal (with hormonal suppression) with ER+/HER2- locally advanced or metastatic breast cancer - Your cancer has progressed after at least one line of hormonal therapy - You have had no more than 2 prior chemotherapy regimens for metastatic disease - You have not received prior SERD therapy (except fulvestrant) - You meet additional arm-specific requirements (e.g., prior CDK4/6 inhibitor for certain combinations) **You may NOT be eligible if...** - Your cancer is HER2-positive or hormone receptor-negative - You have not had prior endocrine therapy - You have had more than 2 prior chemotherapy lines for metastatic disease - You have serious uncontrolled health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.